Department of Anesthesiology, Pain Clinic, Hannover Medical School, Hannover, Germany.
Department of Plastic, Aesthetic, Hand and Reconstructive Surgery, Burn Center, Hannover Medical School, Hannover, Germany.
Cannabis Cannabinoid Res. 2024 Oct;9(5):e1433-e1442. doi: 10.1089/can.2023.0057. Epub 2023 Sep 4.
In the course of the legalization of cannabis for therapeutic purposes in Germany, there has been growing interest in the medical use of cannabinoids. To date, the therapeutic potential of cannabinoids for the treatment of critically ill patients has not been explored. This study aims to understand better whether and how frequently cannabinoids have been administered to critically ill patients in recent years. Initially, a survey was conducted among physicians working in intensive care units (ICUs) at the Hannover Medical School. Subsequently, 653 physicians working in ICUs throughout Germany were surveyed. The frequency and regimen of cannabinoid therapy initiated by the participating physicians in the last 2 years at the time of the survey were characterized. Eight out of 9 physicians at Hannover Medical School and 59 out of 653 physicians in ICUs in Germany participated. At Hannover Medical School, 6 out of 8 physicians and in ICUs in Germany, 16 out of 59 physicians had used cannabinoids in some patients (mainly 9-10) during the 2-year period studied, with dronabinol in doses between 1 and 20 mg being their cannabinoid of choice. Metabolic and psychological distress and medication savings, followed by pain and nausea/vomiting, were the most frequently cited indications for cannabinoid therapy. No relevant safety issues arrived. Lack of personal experience, limited evidence, and gaps in knowledge were the most commonly cited reservations about cannabinoid use. During a 2-year period, dronabinol is used in a few critically ill patients in ICUs. The main indications are to reduce metabolic and psychological distress and to save medication. The majority of participating physicians indicated that the use of cannabinoids in the context of critical care medicine needs further exploration.
在德国，大麻药用合法化的过程中，人们对大麻素的医学用途越来越感兴趣。迄今为止，大麻素治疗危重病患者的治疗潜力尚未得到探索。本研究旨在更好地了解近年来是否以及如何经常向危重病患者使用大麻素。最初，在汉诺威医学院的重症监护病房（ICU）医生中进行了一项调查。随后，对德国各地 ICU 的 653 名医生进行了调查。在调查时的过去 2 年内，参与研究的医生启动的大麻素治疗的频率和方案得到了描述。汉诺威医学院的 9 名医生中有 8 名，德国的 653 名 ICU 医生中有 59 名参加了调查。在汉诺威医学院，8 名医生中有 6 名，德国的 ICU 中，59 名医生中有 16 名在过去 2 年期间的一些患者（主要是 9-10 岁）中使用了大麻素，首选的大麻素是 1 至 20 毫克的大麻二酚。代谢和心理困扰以及药物节省，其次是疼痛和恶心/呕吐，是最常被引用的大麻素治疗指征。没有出现相关的安全问题。缺乏个人经验、证据有限以及知识差距是最常被引用的对大麻素使用的保留意见。在过去的 2 年内，在 ICU 的少数危重病患者中使用了大麻二醇。主要指征是减轻代谢和心理困扰并节省药物。大多数参与调查的医生表示，在重症监护医学背景下使用大麻素需要进一步探索。
